Cost-effectiveness of intrapartum screening and treatment for maternal group B streptococci colonization

D. M. Strickland, E. R. Yeomans, Gary Hankins

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Early-onset neonatal group B streptococci infection occurs in two cases per 1000 live births in the United States and is associated with a mortality rate >20%. Nearly 30% of infected infants have concomitant meningitis and half suffer permanent neurologic damage. Group B streptococci also account for at least 20% of postpartum metritis. The annual cost of group B streptococci infection in the United States is conservatively estimated at nearly 2000 neonatal deaths and >$500 million, excluding the costs of long-term neurologic handicaps. Intrapartum chemoprophylaxis with ampicillin is effective in curtailing transmission of group B streptococci from mother to infant. Methods have been developed to identify maternal colonization before delivery. We applied principles of decision analysis to evaluate cost-effectiveness of intrapartum screening for maternal group B streptococci colonization with various reported methods in cohorts of low- and high-risk women. In the United States intrapartum screening for group B streptococci is cost-effective and offers the potential to avert a significant number of neonatal deaths and postpartum infections.

Original languageEnglish (US)
Pages (from-to)4-8
Number of pages5
JournalAmerican Journal of Obstetrics and Gynecology
Volume163
Issue number1 I
StatePublished - 1990
Externally publishedYes

Fingerprint

Streptococcus agalactiae
Cost-Benefit Analysis
Mothers
Costs and Cost Analysis
Postpartum Period
Nervous System
Therapeutics
Infection
Decision Support Techniques
Chemoprevention
Live Birth
Ampicillin
Meningitis
Mortality

Keywords

  • chemoprophylaxis
  • cost effectiveness
  • Group B streptococcus, rapid screening

ASJC Scopus subject areas

  • Medicine(all)
  • Obstetrics and Gynecology

Cite this

Cost-effectiveness of intrapartum screening and treatment for maternal group B streptococci colonization. / Strickland, D. M.; Yeomans, E. R.; Hankins, Gary.

In: American Journal of Obstetrics and Gynecology, Vol. 163, No. 1 I, 1990, p. 4-8.

Research output: Contribution to journalArticle

@article{ef2eb456655947608f0129432e01b7f6,
title = "Cost-effectiveness of intrapartum screening and treatment for maternal group B streptococci colonization",
abstract = "Early-onset neonatal group B streptococci infection occurs in two cases per 1000 live births in the United States and is associated with a mortality rate >20{\%}. Nearly 30{\%} of infected infants have concomitant meningitis and half suffer permanent neurologic damage. Group B streptococci also account for at least 20{\%} of postpartum metritis. The annual cost of group B streptococci infection in the United States is conservatively estimated at nearly 2000 neonatal deaths and >$500 million, excluding the costs of long-term neurologic handicaps. Intrapartum chemoprophylaxis with ampicillin is effective in curtailing transmission of group B streptococci from mother to infant. Methods have been developed to identify maternal colonization before delivery. We applied principles of decision analysis to evaluate cost-effectiveness of intrapartum screening for maternal group B streptococci colonization with various reported methods in cohorts of low- and high-risk women. In the United States intrapartum screening for group B streptococci is cost-effective and offers the potential to avert a significant number of neonatal deaths and postpartum infections.",
keywords = "chemoprophylaxis, cost effectiveness, Group B streptococcus, rapid screening",
author = "Strickland, {D. M.} and Yeomans, {E. R.} and Gary Hankins",
year = "1990",
language = "English (US)",
volume = "163",
pages = "4--8",
journal = "American Journal of Obstetrics and Gynecology",
issn = "0002-9378",
publisher = "Mosby Inc.",
number = "1 I",

}

TY - JOUR

T1 - Cost-effectiveness of intrapartum screening and treatment for maternal group B streptococci colonization

AU - Strickland, D. M.

AU - Yeomans, E. R.

AU - Hankins, Gary

PY - 1990

Y1 - 1990

N2 - Early-onset neonatal group B streptococci infection occurs in two cases per 1000 live births in the United States and is associated with a mortality rate >20%. Nearly 30% of infected infants have concomitant meningitis and half suffer permanent neurologic damage. Group B streptococci also account for at least 20% of postpartum metritis. The annual cost of group B streptococci infection in the United States is conservatively estimated at nearly 2000 neonatal deaths and >$500 million, excluding the costs of long-term neurologic handicaps. Intrapartum chemoprophylaxis with ampicillin is effective in curtailing transmission of group B streptococci from mother to infant. Methods have been developed to identify maternal colonization before delivery. We applied principles of decision analysis to evaluate cost-effectiveness of intrapartum screening for maternal group B streptococci colonization with various reported methods in cohorts of low- and high-risk women. In the United States intrapartum screening for group B streptococci is cost-effective and offers the potential to avert a significant number of neonatal deaths and postpartum infections.

AB - Early-onset neonatal group B streptococci infection occurs in two cases per 1000 live births in the United States and is associated with a mortality rate >20%. Nearly 30% of infected infants have concomitant meningitis and half suffer permanent neurologic damage. Group B streptococci also account for at least 20% of postpartum metritis. The annual cost of group B streptococci infection in the United States is conservatively estimated at nearly 2000 neonatal deaths and >$500 million, excluding the costs of long-term neurologic handicaps. Intrapartum chemoprophylaxis with ampicillin is effective in curtailing transmission of group B streptococci from mother to infant. Methods have been developed to identify maternal colonization before delivery. We applied principles of decision analysis to evaluate cost-effectiveness of intrapartum screening for maternal group B streptococci colonization with various reported methods in cohorts of low- and high-risk women. In the United States intrapartum screening for group B streptococci is cost-effective and offers the potential to avert a significant number of neonatal deaths and postpartum infections.

KW - chemoprophylaxis

KW - cost effectiveness

KW - Group B streptococcus, rapid screening

UR - http://www.scopus.com/inward/record.url?scp=0025148690&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025148690&partnerID=8YFLogxK

M3 - Article

VL - 163

SP - 4

EP - 8

JO - American Journal of Obstetrics and Gynecology

JF - American Journal of Obstetrics and Gynecology

SN - 0002-9378

IS - 1 I

ER -